Expanded Haemodialysis As a Current Strategy to Remove Uremic Toxins

Overview

Journal Toxins (Basel)

Publisher MDPI

Specialty Toxicology

Date 2021 Jun 2

PMID 34073439

Citations 7

Authors

Paola Ciceri

Mario Cozzolino

Affiliations

Soon will be listed here.

Abstract

Chronic kidney disease (CKD) is characterized by the retention of solutes named uremic toxins, which strongly associate with high morbidity and mortality. Mounting evidence suggests that targeting uremic toxins and/or their pathways may decrease the risk of cardiovascular disease in CKD patients. Dialysis therapies have been developed to improve removal of uremic toxins. Advances in our understanding of uremic retention solutes as well as improvements in dialysis membranes and techniques (HDx, Expanded Hemodialysis) will offer the opportunity to ameliorate clinical symptoms and outcomes, facilitate personalized and targeted dialysis treatment, and improve quality of life, morbidity and mortality.

Citing Articles

Development of Hollow Fiber Membranes Suitable for Outside-In Filtration of Human Blood Plasma.

Ramada D, Adema B, Labib M, Ter Beek O, Stamatialis D Membranes (Basel). 2025; 15(1).

PMID: 39852257 PMC: 11766680. DOI: 10.3390/membranes15010016.

Future of Uremic Toxin Management.

Vanholder R, Snauwaert E, Verbeke F, Glorieux G Toxins (Basel). 2024; 16(11).

PMID: 39591217 PMC: 11598275. DOI: 10.3390/toxins16110463.

Trial design of the MOTheR HDx study: a multicenter, open-label, prospective, randomized study to explore the morbidity and mortality in patients dialyzed with the Theranova HDx in comparison with online hemodiafiltration.

de Sequera P, Perez-Garcia R, Vega A, Martinez-Vaquera S, Acosta J, Perez Del Valle K Clin Kidney J. 2023; 16(11):2254-2261.

PMID: 37915938 PMC: 10616438. DOI: 10.1093/ckj/sfad128.

Medium cut-off dialyzer for middle molecular uremic toxins in AKI and chronic dialysis.

Fiorentino M, La Fergola F, De Rosa S J Nephrol. 2023; 37(1):23-37.

PMID: 37843731 PMC: 10920419. DOI: 10.1007/s40620-023-01771-0.

Cytokine and Chemokine Retention Profile in COVID-19 Patients with Chronic Kidney Disease.

Ciceri P, Bono V, Magagnoli L, Sala M, Monforte A, Galassi A Toxins (Basel). 2022; 14(10).

PMID: 36287942 PMC: 9611576. DOI: 10.3390/toxins14100673.

References

Cozzolino M, Mangano M, Stucchi A, Ciceri P, Conte F, Galassi A . Cardiovascular disease in dialysis patients. Nephrol Dial Transplant. 2018; 33(suppl_3):iii28-iii34. PMC: 6168816. DOI: 10.1093/ndt/gfy174. View

Fraser S, Fenton A, Harris S, Shardlow A, Liabeuf S, Massy Z . The Association of Serum Free Light Chains With Mortality and Progression to End-Stage Renal Disease in Chronic Kidney Disease: Systematic Review and Individual Patient Data Meta-analysis. Mayo Clin Proc. 2017; 92(11):1671-1681. DOI: 10.1016/j.mayocp.2017.08.021. View

Bunch A, Sanchez R, Nilsson L, Bernardo A, Vesga J, Ardila F . Medium cut-off dialyzers in a large population of hemodialysis patients in Colombia: COREXH registry. Ther Apher Dial. 2020; 25(1):33-43. PMC: 7818220. DOI: 10.1111/1744-9987.13506. View

Yeter H, Korucu B, Akcay O, Derici K, Derici U, Arinsoy T . Effects of medium cut-off dialysis membranes on inflammation and oxidative stress in patients on maintenance hemodialysis. Int Urol Nephrol. 2020; 52(9):1779-1789. DOI: 10.1007/s11255-020-02562-3. View

Shafi T, Parekh R, Jaar B, Plantinga L, Oberai P, Eckfeldt J . Serum β-trace protein and risk of mortality in incident hemodialysis patients. Clin J Am Soc Nephrol. 2012; 7(9):1435-45. PMC: 3430954. DOI: 10.2215/CJN.02240312. View

Kirsch A, Lyko R, Nilsson L, Beck W, Amdahl M, Lechner P . Performance of hemodialysis with novel medium cut-off dialyzers. Nephrol Dial Transplant. 2016; 32(1):165-172. PMC: 5837492. DOI: 10.1093/ndt/gfw310. View

Allawati H, Dallas L, Nair S, Palmer J, Thaikandy S, Hutchison C . A Pharmacokinetic Study Comparing the Clearance of Vancomycin during Haemodialysis Using Medium Cut-Off Membrane (Theranova) and High-Flux Membranes (Revaclear). Toxins (Basel). 2020; 12(5). PMC: 7290329. DOI: 10.3390/toxins12050317. View

Reis T, Martino F, Dias P, de Freitas G, da Silva Filho E, de Azevedo M . Removal of middle molecules with medium cutoff dialyzer in patients on short frequent hemodialysis. Hemodial Int. 2020; 25(2):180-187. DOI: 10.1111/hdi.12906. View

Puthumana J, Thiessen-Philbrook H, Xu L, Coca S, Garg A, Himmelfarb J . Biomarkers of inflammation and repair in kidney disease progression. J Clin Invest. 2020; 131(3). PMC: 7843225. DOI: 10.1172/JCI139927. View

10.

Goicoechea M, de Vinuesa S, Gomez-Campdera F, Luno J . Predictive cardiovascular risk factors in patients with chronic kidney disease (CKD). Kidney Int Suppl. 2004; (93):S35-8. DOI: 10.1111/j.1523-1755.2005.09308.x. View

11.

Ciceri P, Falleni M, Tosi D, Martinelli C, Cannizzo S, Marchetti G . Therapeutic Effect of Iron Citrate in Blocking Calcium Deposition in High Pi-Calcified VSMC: Role of Autophagy and Apoptosis. Int J Mol Sci. 2019; 20(23). PMC: 6928632. DOI: 10.3390/ijms20235925. View

12.

Ciceri P, Galassi A, Alfieri C, Messa P, Cozzolino M . Uremic Patients with Increased Vascular Calcification Score Have Serum with High Calcific Potential: Role of Vascular Smooth Muscle Cell Osteoblastic Differentiation and Apoptosis. Blood Purif. 2019; 48(2):142-149. DOI: 10.1159/000497229. View

13.

Alarcon J, Bunch A, Ardila F, Zuniga E, Vesga J, Rivera A . Impact of Medium Cut-Off Dialyzers on Patient-Reported Outcomes: COREXH Registry. Blood Purif. 2020; 50(1):110-118. DOI: 10.1159/000508803. View

14.

Liabeuf S, Lenglet A, Desjardins L, Neirynck N, Glorieux G, Lemke H . Plasma beta-2 microglobulin is associated with cardiovascular disease in uremic patients. Kidney Int. 2012; 82(12):1297-303. DOI: 10.1038/ki.2012.301. View

15.

Carrero J, Kyriazis J, Sonmez A, Tzanakis I, Qureshi A, Stenvinkel P . Prolactin levels, endothelial dysfunction, and the risk of cardiovascular events and mortality in patients with CKD. Clin J Am Soc Nephrol. 2011; 7(2):207-15. PMC: 3280028. DOI: 10.2215/CJN.06840711. View

16.

Rambabova Bushljetik I, Trajceska L, Biljali S, Balkanov T, Dejanov P, Spasovski G . Efficacy of Medium Cut-Off Dialyzer and Comparison with Standard High-Flux Hemodialysis. Blood Purif. 2020; 50(4-5):492-498. DOI: 10.1159/000511983. View

17.

Krishnasamy R, Hawley C, Jardine M, Roberts M, Cho Y, Wong M . A tRial Evaluating Mid Cut-Off Value Membrane Clearance of Albumin and Light Chains in HemoDialysis Patients: A Safety Device Study. Blood Purif. 2020; 49(4):468-478. DOI: 10.1159/000505567. View

18.

Belmouaz M, Bauwens M, Hauet T, Bossard V, Jamet P, Joly F . Comparison of the removal of uraemic toxins with medium cut-off and high-flux dialysers: a randomized clinical trial. Nephrol Dial Transplant. 2019; 35(2):328-335. DOI: 10.1093/ndt/gfz189. View

19.

Jalal D, Sanford B, Renner B, Ten Eyck P, Laskowski J, Cooper J . Detection of pro angiogenic and inflammatory biomarkers in patients with CKD. Sci Rep. 2021; 11(1):8786. PMC: 8062467. DOI: 10.1038/s41598-021-87710-0. View

20.

Belmouaz M, Diolez J, Bauwens M, Duthe F, Ecotiere L, Desport E . Comparison of hemodialysis with medium cut-off dialyzer and on-line hemodiafiltration on the removal of small and middle-sized molecules . Clin Nephrol. 2017; 89 (2018)(1):50-56. DOI: 10.5414/CN109133 . View